Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Dec;22(6):739–743. doi: 10.1111/j.1365-2125.1986.tb02969.x

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.

C J Speirs, S Murray, A R Boobis, C E Seddon, D S Davies
PMCID: PMC1401220  PMID: 3567021

Abstract

Quinidine and its diastereoisomer quinine were tested in vitro for their effect on the 4-hydroxylation of debrisoquine, the O-deethylation of phenacetin and the 1'-hydroxylation of bufuralol, by human liver microsomal samples; quinidine was studied for its effect on debrisoquine 4-hydroxylation in vivo. Quinidine was a potent inhibitor of the 4-hydroxylation of debrisoquine and the 1'-hydroxylation of bufuralol, with IC50 values of 0.7 and 0.2 microM, being around 100 times more potent in this respect than quinine. Very much higher (1000-fold) levels of quinidine were required to inhibit the O-deethylation of phenacetin, being rather less potent in this than quinine. Eight subjects were phenotyped for their debrisoquine oxidation status and found to be extensive metabolisers (EM). They were tested again after the co-administration of 50 mg of quinidine with the debrisoquine. The concomitant administration of quinidine increased the metabolic ratios (MRs) by a mean of 26-fold. The effects of quinidine at a dose of only 50 mg, on the metabolism of a new drug in EM subjects may prove a useful method of assessing the contribution of the debrisoquine 4-hydroxylase isozyme to the elimination of the drug tested.

Full text

PDF
739

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boobis A. R., Murray S., Hampden C. E., Davies D. S. Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities. Biochem Pharmacol. 1985 Jan 1;34(1):65–71. doi: 10.1016/0006-2952(85)90101-7. [DOI] [PubMed] [Google Scholar]
  2. Boobis A. R., Murray S., Kahn G. C., Robertz G. M., Davies D. S. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man. Mol Pharmacol. 1983 Mar;23(2):474–481. [PubMed] [Google Scholar]
  3. Davies D. S., Kahn G. C., Murray S., Brodie M. J., Boobis A. R. Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver. Br J Clin Pharmacol. 1981 Jan;11(1):89–91. doi: 10.1111/j.1365-2125.1981.tb01108.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Distlerath L. M., Reilly P. E., Martin M. V., Davis G. G., Wilkinson G. R., Guengerich F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1985 Jul 25;260(15):9057–9067. [PubMed] [Google Scholar]
  5. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Guentert T. W., Holford N. H., Coates P. E., Upton R. A., Riegelman S. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies. J Pharmacokinet Biopharm. 1979 Aug;7(4):315–330. doi: 10.1007/BF01062532. [DOI] [PubMed] [Google Scholar]
  7. Haley C. S., Waring R. H., Mitchell S. C., Shah R. R., Idle J. R., Smith R. L. Lack of congruence of S-carboxymethyl-L-cysteine sulphoxidation and debrisoquine 4-hydroxylation in a Caucasian population. Xenobiotica. 1985 May;15(5):445–450. doi: 10.3109/00498258509045015. [DOI] [PubMed] [Google Scholar]
  8. Hori R., Okumura K., Inui K., Yasuhara M., Yamada K., Sakurai T., Kawai C. Quinidine-induced rise in ajmaline plasma concentration. J Pharm Pharmacol. 1984 Mar;36(3):202–204. doi: 10.1111/j.2042-7158.1984.tb06942.x. [DOI] [PubMed] [Google Scholar]
  9. Inaba T., Jurima M., Mahon W. A., Kalow W. In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metab Dispos. 1985 Jul-Aug;13(4):443–448. [PubMed] [Google Scholar]
  10. Jacqz E., Hall S. D., Branch R. A., Wilkinson G. R. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital. Clin Pharmacol Ther. 1986 Jun;39(6):646–653. doi: 10.1038/clpt.1986.113. [DOI] [PubMed] [Google Scholar]
  11. Kahn G. C., Boobis A. R., Brodie M. J., Toverud E. L., Murray S., Davies D. S. Phenacetin O-deethylase: an activity of a cytochrome P-450 showing genetic linkage with that catalysing the 4-hydroxylation of debrisoquine? Br J Clin Pharmacol. 1985 Jul;20(1):67–76. doi: 10.1111/j.1365-2125.1985.tb02800.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Leemann T., Dayer P., Meyer U. A. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. Eur J Clin Pharmacol. 1986;29(6):739–741. doi: 10.1007/BF00615971. [DOI] [PubMed] [Google Scholar]
  13. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  14. Murray S., Boobis A. R. An assay for paracetamol, produced by the O-deethylation of phenacetin in vitro, using gas chromatography/electron capture negative ion chemical ionization mass spectrometry. Biomed Environ Mass Spectrom. 1986 Feb;13(2):91–93. doi: 10.1002/bms.1200130208. [DOI] [PubMed] [Google Scholar]
  15. Otton S. V., Inaba T., Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sci. 1984 Jan 2;34(1):73–80. doi: 10.1016/0024-3205(84)90332-1. [DOI] [PubMed] [Google Scholar]
  16. Shah R. R., Oates N. S., Idle J. R., Smith R. L., Lockhart J. D. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 1982 Jan 30;284(6312):295–299. doi: 10.1136/bmj.284.6312.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Silas J. H., Lennard M. S., Tucker G. T., Smith A. J., Malcolm S. L., Marten T. R. The disposition of debrisoquine in hypertensive patients. Br J Clin Pharmacol. 1978 Jan;5(1):27–34. doi: 10.1111/j.1365-2125.1978.tb01594.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Silas J. H., Tucker G. T., Smith A. J., Fieller N. R. Accumulation of debrisoquine by platelets in vivo: a model of events at the peripheral adrenergic neurone. Br J Clin Pharmacol. 1980 Apr;9(4):419–425. doi: 10.1111/j.1365-2125.1980.tb01071.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Sloan T. P., Idle J. R., Smith R. L. Influence of DH/DL alleles regulating debrisoquine oxidation on phenytoin hydroxylation. Clin Pharmacol Ther. 1981 Apr;29(4):493–497. doi: 10.1038/clpt.1981.68. [DOI] [PubMed] [Google Scholar]
  20. Waring R. H., Mitchell S. C., Idle J. R., Smith R. L. Genetically determined impaired drug sulphoxidation. Lancet. 1981 Apr 4;1(8223):778–778. doi: 10.1016/s0140-6736(81)92647-7. [DOI] [PubMed] [Google Scholar]
  21. de Wolff F. A., Vermeij P., Ferrari M. D., Buruma O. J., Breimer D. D. Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Ther Drug Monit. 1983 Jun;5(2):213–215. doi: 10.1097/00007691-198306000-00011. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES